Effects of sildenafil on myocardial blood flow in humans with ischemic heart disease.

Background We tested the hypothesis that sildenafil increases myocardial dilator reserve in humans with ischemic heart disease. Methods Positron emission tomography measured myocardial blood flow in 14 patients with ischemic heart disease. Patients were studied twice, in double-blind, placebo-control, cross-over design with sildenafil (or placebo) given ∼2-3 before measurements of hemodynamics and myocardial blood flow: at rest, with cold pressor stress and with adenosine. All myocardial segments of each patient with myocardial blood flow 1.65ml/minperg were averaged and combined into a normal zone for that patient. Results At rest, rate pressure product (heart rate × systolic arterial pressure, mmHg/min) was comparable, as was abnormal zone myocardial blood flow (ml/minperg; 0.76 ′ 0.48 placebo versus 0.64 ′ 0.20 sildenafil, both P=NS; mean ′ SD). Both rate pressure product and myocardial blood flow increased (P<0.01) with cold pressor stress (11 ′ 3 K and 1.14′0.59 placebo versus 10′3 K and 1.21 ′ 0.62 sildenafil). However, sildenafil failed to improve the myocardial blood flow response to cold pressor stress in abnormal or normal zones. In contrast, abnormal zone myocardial blood flow reserve with adenosine and sildenafil (2.6 ′ 0.7) exceeded that with adenosine and placebo (2.0 ′ 1.3, P< 0.04, paired sign test). Conclusion Sildenafil improves myocardial blood flow dilator response to adenosine in abnormal zones, possibly by augmenting nitric oxide-mediated increases in cGMP because adenosine response in part is nitric oxide dependent. Failure to improve myocardial blood flow response to cold pressor stress suggests that α-adrenergic constriction may offset enhanced nitric oxide effects. Clinically, the data suggest sildenafil may exert an anti-ischemic effect in patients with coronary artery disease.